William Blair Increases Earnings Estimates for Genmab A/S

Genmab A/S (NASDAQ:GMAB) – Equities research analysts at William Blair increased their FY2024 earnings estimates for Genmab A/S in a research report issued on Wednesday, November 6th. William Blair analyst M. Phipps now anticipates that the company will post earnings of $1.24 per share for the year, up from their prior forecast of $1.22. The consensus estimate for Genmab A/S’s current full-year earnings is $1.29 per share. William Blair also issued estimates for Genmab A/S’s Q4 2024 earnings at $0.34 EPS, FY2025 earnings at $1.60 EPS, FY2026 earnings at $2.52 EPS and FY2027 earnings at $3.56 EPS.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a net margin of 23.49% and a return on equity of 14.73%. The business had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million.

GMAB has been the topic of a number of other research reports. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a report on Friday. Redburn Atlantic began coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. Truist Financial decreased their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Wednesday, October 16th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Trading Down 0.1 %

Shares of Genmab A/S stock opened at $23.08 on Friday. Genmab A/S has a 1 year low of $21.90 and a 1 year high of $32.89. The company has a market cap of $15.27 billion, a P/E ratio of 22.41, a P/E/G ratio of 0.66 and a beta of 0.99. The stock has a 50-day moving average price of $24.39 and a 200 day moving average price of $26.41.

Institutional Investors Weigh In On Genmab A/S

A number of large investors have recently bought and sold shares of GMAB. Russell Investments Group Ltd. lifted its position in shares of Genmab A/S by 137.7% in the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after buying an additional 544 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Genmab A/S in the 1st quarter worth approximately $43,000. Blue Trust Inc. boosted its position in Genmab A/S by 892.0% during the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after purchasing an additional 3,880 shares during the period. Headlands Technologies LLC grew its holdings in Genmab A/S by 1,702.8% during the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after purchasing an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its position in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after purchasing an additional 478 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.